Antiviral activity of favipiravir against Zika and SARS-CoV-2 in cynomolgus macaques Efficacy SARSCoV2 Coronavirus Disease COVID NatureComms
By Suchandrima BhowmikSep 4 2022Reviewed by Benedette Cuffari, M.Sc. Favipiravir inhibits viral ribonucleic acid polymerase and has been approved for the treatment of noncomplicated influenza infections in Japan and is currently being studied in clinical trials in the United States. Previous studies have shown strong antiviral activity of T-705 against several RNA viruses, such as Ebola, Marburg, and Lassa viruses, both in vitro and in macaques.
The antiviral efficacy of F-705 in these studies was found to be lower or comparable to those observed in human trials. However, the toxicity of the agent observed in some animals was difficult to translate to human doses. The first experiment assessed the pharmacokinetics of T-705 in four uninfected animals. These animals were administered a loading dose of 250 mg/kg twice a day on the first day through the intravenous route. The animals were subsequently administered a maintenance dose of 150 mg/kg BID subcutaneously for 14 days.
Exposure to 10^6 pfu of SARS-CoV-2 was completed two days post-treatment. Atropine was used for pre-medication, while medetomidine and ketamine were used for anesthesia. Animals were euthanized seven days post-exposure. In the second experiment, animals exposed to ZIKV and treated with T-705 showed lower viral loads as compared to untreated animals. The peak viral replication and overall viral shedding were also lower in treated animals as compared to untreated animals.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A journal dedicated to studying the combined effects of activity, sedentary and sleep behaviours - Journal of Activity, Sedentary and Sleep Behaviors
Read more »
PQube accused by second indie developer over withheld paymentsIn the wake of a recent claim against publisher PQube, Corecell Technology, the developers behind AeternoBlade II, has also made an accusation against PQube, claiming the publisher withheld payments.
Read more »
Brighton's XI against Leicester shows how good they're in the transfer market, it's world class recruitmentBrighton have a great manager, an incredible recruitment system and a healthy net spend. They're flying in the Premier League this season 👏
Read more »